Ambrilia Biopharma Inc announced that it has succeeded in manufacturing a final one-month formulation of goserelin intended for the treatment of prostate cancer and several gynaecological indications. The company has already developed a proprietary, novel three-month formulation of goserelin for which a phase-I/II clinical programme in prostate cancer patients was initiated in July 2008.

"With the addition of a one-month goserelin formulation we now offer to interested acquirers a complete generic Zoladex package which includes a potentially first-to-market three-month generic version. This further enhances the value of our goserelin product offering focused on European market and maximizes potential deal terms," said Philippe Calais, president and CEO. He concluded, "All efforts are being made in order to conclude an agreement by the end of 2008."

The goserelin formulations are manufactured by Ambrilia at its GMP (Good Manufacturing Practice) facilities in Montreal.

Ambrilia has developed novel formulations of the 3.8mg (1-month depot) and 10.8mg (three-month depot) versions of Zoladex (goserelin), a Luteinizing Hormone-Releasing Hormone (LHRH) analogue indicated for hormone-sensitive prostate cancer and several gynaecological indications such as fibro-myomas and endometriosis.